ICRP Publication 94: Release of Patients after Therapy with Unsealed Radionuclides (Annals of the ICRP)

0 avg rating
( 0 ratings by GoodReads )
 
9780080445601: ICRP Publication 94: Release of Patients after Therapy with Unsealed Radionuclides (Annals of the ICRP)

After some therapeutic nuclear medicine procedures with unsealed radionuclides, precautions may be needed to limit doses to other people, but this is rarely the case after diagnostic procedures. Iodine-131 results in the largest dose to medical staff, the public, caregivers, and relatives. Other radionuclides used in therapy are usually simple beta emitters (e.g. phosphorus-32, strontium-89, and yttrium-90) that pose much less risk. Dose limits apply to exposure of the public and medical staff from patients. Previously, the ICRP has recommended that a source-related dose constraint for optimisation of a few mSv/episode applies to relatives, visitors, and caregivers at home, rather than a dose limit. The present report recommends that young children and infants, as well as visitors not engaged in direct care or comforting, should be treated as members of the public (i.e. be subject to the public dose limit). 

The modes of exposure to other people are: external exposure; internal exposure due to contamination; and environmental pathways. Dose to adults from patients is mainly due to external exposure. Contamination of infants and children with saliva from a patient could result in significant doses to the child’s thyroid. It is important to avoid contamination of children and pregnant women. After radioiodine therapy, mothers must cease breastfeeding immediately. Many types of therapy with unsealed radionuclides are contraindicated in pregnant females. Women should not become pregnant for some time after radioisotope therapy. Technetium-99m dominates discharges to the environment from excreta of nuclear medicine patients, but its short half-life limits its importance. The second largest discharges, iodine-131, can be detected in the environment after medical uses but with no measurable environmental impact. Storing patients' urine after therapy appears to have minimal benefit.

"synopsis" may belong to another edition of this title.

Product Description:

After some therapeutic nuclear medicine procedures with unsealed radionuclides, precautions may be needed to limit doses to others, but this is rarely the case after diagnostic procedures. Iodine-131 results in the most dose to medical staff, public, caregivers, and family members. Other radionuclides used in therapy are usually simple beta emitters (e.g. 32P, 89Sr, 90Y) that pose much less hazard. Dose limits apply to the exposure of the public and medical staff from patients. Prior ICRP recommendations are that no dose limit but a source-related dose constraint for optimisation of a few mSv per episode applies to the family, visitors, and caregivers at home. Here, it is recommended that young children and infants, as well as visitors not engaged in direct care or comforting, be treated as members of the public (i.e., be subject to the public dose limit).

"About this title" may belong to another edition of this title.

Buy New View Book
List Price: US$ 160.00
US$ 256.00

Convert Currency

Shipping: FREE
Within U.S.A.

Destination, Rates & Speeds

Add to Basket

Top Search Results from the AbeBooks Marketplace

1.

ICRP
Published by SAGE Publications Ltd (2005)
ISBN 10: 0080445608 ISBN 13: 9780080445601
New Paperback Quantity Available: 1
Seller
Irish Booksellers
(Rumford, ME, U.S.A.)
Rating
[?]

Book Description SAGE Publications Ltd, 2005. Paperback. Book Condition: New. book. Bookseller Inventory # 80445608

More Information About This Seller | Ask Bookseller a Question

Buy New
US$ 256.00
Convert Currency

Add to Basket

Shipping: FREE
Within U.S.A.
Destination, Rates & Speeds